MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria’s CEO, Dr. Stephen L. Hoffman, awarded the Clara Southmayd Ludlow Medal at the American Society of Tropical Medicine and Hygiene’s annual conference
On November 15th, Dr. Stephen L. Hoffman was awarded the Clara Southmayd Ludlow Medal at the American Society of Tropical Medicine and Hygiene’s annual conference which recognizes honorees for inspirational and pioneering spirit, whose work represents success despite obstacles, and advances the field of tropical medicine. Clara Southmayd Ludlow was an entomologist with scientific zeal and tenacity who battled the odds of age, gender and skepticism of women in the sciences to advance the understanding of tropical medicine.
EU Malaria Fund: Sanaria to receive financing to develop Malaria vaccine
Sanaria to receive €12.9M for the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine from the EU Malaria Fund.
Sanaria PfSPZ Vaccines Wins Highly Commended Prophylactic Vaccine at the 13th Annual Vaccine Industry Excellence Awards
Sanaria's PfSPZ vaccines were shortlisted at the VIE awards with: Pfizer, Takeda, Janssen, Merck, Inovio, Geneone/Inovio, and BiondVax.
Sanaria’s Chief Executive and Scientific Officer, Dr. Hoffman, recognized as one of Ten International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health in BioBuzz
Dr. Stephen Hoffman, Sanaria's Chief Executive and Scientific Officer was recognized by BioBuzz as one of ten international vaccine influencers who exemplify Maryland's leading role in public health.
Sanaria’s Patents for Humanity Award Recognized in Virtual Ceremony hosted by the USPTO
Sanaria is recognized by USPTO in virtual ceremony for their Patents for Humanity Award.
Sanaria and Protein Potential Welcome Guest Speaker Dr. Golightly Who Spoke About Antiracism: Moving Beyond Good Hearts and Intentions
On September 1st, Sanaria and Protein Potential welcomed Dr. Linnie Golightly who presented on Antiracism.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.